Chloroquine Retinopathy, Proliferative Nephritis
Conditions
Brief summary
Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .
Detailed description
All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria. The criteria set developed by the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV . Inclusion Criteria: * Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV. * All patients will be received steroids , MMF and Angiotensin Converting Enzyme. Exclusion Criteria: * Patients diagnosed with lupus nephritis class I,II,V and VI. * Patients received Cyclophosphamide in stead of MMF.
Interventions
DRUGChloroquine
group1 received chloroquine .
DRUGHydroxychloroquine
Group 2 received hydroxychloroquine
Sponsors
Tanta University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
10 Years to 18 Years
Inclusion criteria
* Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV. * All patients will be received steroids , MMF and Angiotensin Converting Enzyme.
Exclusion criteria
* Patients diagnosed with lupus nephritis class I,II,V and VI. * Patients received Cyclophosphamide in stead of MMF.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fundus examination as screening test | 12 months | Detection of chloroquine and hydroxychloroquine related retinal toxicity at early stage. |
Countries
Egypt
Contacts
Primary ContactFatma S Gheet, M.B.,BCh
Outcome results
None listed